Prevalence of sarcopenia in patients with advanced intestinal neuroendocrine neoplasms at time of diagnosis

#4171

Introduction: Sarcopenia is defined as the loss of muscle mass, strength, and physical performance. First-line therapy for NENs includes somatostatin analogues (SSAs), which could be responsible for malabsorption conditions (e.g. exocrine pancreatic insufficiency - EPI), that can affect clinical outcomes and treatment response. However, the relationship between sarcopenia and NENs is still lacking in the literature.

Aim(s): To assess the prevalence of sarcopenia in pts with NENs at diagnosis time before initiation of SSAs therapy.

Materials and methods: Retrospective single-center study including consecutive patients with advanced gastrointestinal G1/G2 NENs. CT scan was analysed at time of diagnosis. Sarcopenia was assessed through segmentation at L3 lumbar vertebra level with a dedicated software. Skeletal muscle Index (SMI) was obtained (cut-off values were <52.4 cm2/m2 and<38.5 cm2/m2 in men and women, respectively).

Conference:

Presenting Author: Marasco M

Authors: Romano E, Polici M, Lerose F, Marasco M, Nardacci S,

Keywords: malnutrition, sarcopenia, somatostatin analogues, exocrine pancreatic insufficiency,